Lyka Labs Limited (LYKALABS.NS)
INR 156.41
(1.68%)
INR 156.41
(1.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 599.4 Million INR | -55.09% |
| 2022 | 531.29 Million INR | 12.58% |
| 2021 | 471.93 Million INR | 168.71% |
| 2020 | 175.63 Million INR | -51.14% |
| 2019 | 359.48 Million INR | 4.74% |
| 2018 | 343.2 Million INR | -17.59% |
| 2017 | 416.43 Million INR | -13.8% |
| 2016 | 483.07 Million INR | 118.19% |
| 2015 | 221.4 Million INR | -61.53% |
| 2014 | 575.54 Million INR | 7.93% |
| 2013 | 533.25 Million INR | 3.31% |
| 2012 | 516.16 Million INR | 0.0% |
| 2011 | - INR | -100.0% |
| 2010 | 189.99 Million INR | -3.53% |
| 2009 | 196.93 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 67.17 Million INR | 2.7% |
| 2023 Q2 | 157.12 Million INR | 10.73% |
| 2023 FY | 238.62 Million INR | -55.09% |
| 2023 Q3 | 168.61 Million INR | 7.31% |
| 2023 Q1 | 141.9 Million INR | -3.95% |
| 2023 Q4 | 65.4 Million INR | -61.21% |
| 2022 Q3 | 130.9 Million INR | -0.26% |
| 2022 Q2 | 131.24 Million INR | 8.08% |
| 2022 Q1 | 121.42 Million INR | 30.71% |
| 2022 FY | 531.29 Million INR | 12.58% |
| 2022 Q4 | 147.73 Million INR | 12.85% |
| 2021 Q3 | 107.52 Million INR | -34.15% |
| 2021 Q2 | 163.29 Million INR | 50.89% |
| 2021 Q1 | 108.22 Million INR | 224.89% |
| 2021 FY | 471.93 Million INR | 168.71% |
| 2021 Q4 | 92.89 Million INR | -13.61% |
| 2020 Q2 | 86.72 Million INR | 10.39% |
| 2020 FY | 175.63 Million INR | -51.14% |
| 2020 Q3 | 97 Million INR | 11.85% |
| 2020 Q4 | -86.65 Million INR | -189.33% |
| 2020 Q1 | 78.56 Million INR | 32.28% |
| 2019 Q4 | 59.39 Million INR | -40.44% |
| 2019 Q1 | 93.34 Million INR | 78.02% |
| 2019 FY | 359.48 Million INR | 4.74% |
| 2019 Q2 | 88.72 Million INR | -4.95% |
| 2019 Q3 | 99.71 Million INR | 12.39% |
| 2018 Q2 | 122.47 Million INR | -69.94% |
| 2018 Q4 | 52.43 Million INR | -19.13% |
| 2018 FY | 343.2 Million INR | -17.59% |
| 2018 Q1 | 407.45 Million INR | 0.0% |
| 2018 Q3 | 64.83 Million INR | -47.06% |
| 2017 FY | 416.43 Million INR | -13.8% |
| 2016 Q1 | 120.68 Million INR | -66.2% |
| 2016 FY | 483.07 Million INR | 118.19% |
| 2016 Q4 | 101.46 Million INR | -20.03% |
| 2016 Q3 | 126.87 Million INR | -1.35% |
| 2016 Q2 | 128.61 Million INR | 6.57% |
| 2015 Q2 | 49.32 Million INR | -66.25% |
| 2015 Q4 | 357.06 Million INR | 203.74% |
| 2015 Q3 | 117.55 Million INR | 138.35% |
| 2015 Q1 | 146.11 Million INR | -12.19% |
| 2015 FY | 221.4 Million INR | -61.53% |
| 2014 Q2 | 21.57 Million INR | -76.13% |
| 2014 Q1 | 90.4 Million INR | 0.0% |
| 2014 Q4 | 166.39 Million INR | 5.04% |
| 2014 Q3 | 158.4 Million INR | 634.12% |
| 2014 FY | 575.54 Million INR | 7.93% |
| 2013 Q3 | 77.72 Million INR | -23.74% |
| 2013 FY | 533.25 Million INR | 3.31% |
| 2013 Q1 | 89.64 Million INR | -68.17% |
| 2013 Q2 | 101.91 Million INR | 13.69% |
| 2012 Q2 | 89.12 Million INR | 14.85% |
| 2012 Q4 | 281.64 Million INR | 243.44% |
| 2012 Q3 | 82 Million INR | -7.99% |
| 2012 FY | 516.16 Million INR | 0.0% |
| 2012 Q1 | 77.6 Million INR | 0.0% |
| 2011 FY | - INR | -100.0% |
| 2011 Q3 | 77.58 Million INR | 0.0% |
| 2010 FY | 189.99 Million INR | -3.53% |
| 2009 FY | 196.93 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biocon Limited | 40.9 Billion INR | 98.535% |
| Blue Jet Healthcare Limited | 531.85 Million INR | -12.702% |
| Concord Biotech Limited | 1.45 Billion INR | 58.936% |
| Dishman Carbogen Amcis Limited | 5.14 Billion INR | 88.355% |
| Jubilant Ingrevia Limited | 6.67 Billion INR | 91.013% |
| Panacea Biotec Limited | 1.99 Billion INR | 69.961% |
| Piramal Pharma Limited | 19.91 Billion INR | 96.99% |
| SMS Lifesciences India Limited | 602.96 Million INR | 0.59% |
| Supriya Lifescience Limited | 1.08 Billion INR | 44.507% |
| Syngene International Limited | 5.99 Billion INR | 90.002% |
| TAKE Solutions Limited | 396.91 Million INR | -51.018% |
| Zota Health Care Limited | 457.83 Million INR | -30.922% |